DK0644755T3 - Overflademodificerede NSAID-nanopartikler - Google Patents
Overflademodificerede NSAID-nanopartiklerInfo
- Publication number
- DK0644755T3 DK0644755T3 DK93914224.6T DK93914224T DK0644755T3 DK 0644755 T3 DK0644755 T3 DK 0644755T3 DK 93914224 T DK93914224 T DK 93914224T DK 0644755 T3 DK0644755 T3 DK 0644755T3
- Authority
- DK
- Denmark
- Prior art keywords
- surface modified
- modified nsaid
- nsaid nanoparticles
- nanoparticles
- maintain
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Pain & Pain Management (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pigments, Carbon Blacks, Or Wood Stains (AREA)
- Powder Metallurgy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89719392A | 1992-06-10 | 1992-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0644755T3 true DK0644755T3 (da) | 1997-09-22 |
Family
ID=25407503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93914224.6T DK0644755T3 (da) | 1992-06-10 | 1993-06-01 | Overflademodificerede NSAID-nanopartikler |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0644755B1 (da) |
JP (2) | JP4439590B2 (da) |
AT (1) | ATE150297T1 (da) |
AU (1) | AU677783B2 (da) |
CA (1) | CA2118517C (da) |
DE (1) | DE69309056T2 (da) |
DK (1) | DK0644755T3 (da) |
ES (1) | ES2101323T3 (da) |
GR (1) | GR3022880T3 (da) |
HU (1) | HUT70952A (da) |
MX (1) | MX9303452A (da) |
WO (1) | WO1993025190A1 (da) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
WO1999017744A1 (en) * | 1997-10-07 | 1999-04-15 | Fuisz Technologies Ltd. | Immediate release drug delivery forms |
US6013280A (en) * | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
IE980115A1 (en) * | 1998-02-16 | 2000-02-09 | Biovail Internat Ltd | Solubilizing delivery systems and method of manufacture |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
CA2346001C (en) * | 1998-10-01 | 2003-12-30 | Elan Pharma International, Limited | Controlled release nanoparticulate compositions |
UA74539C2 (en) | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
MY120279A (en) | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
CA2461080A1 (en) | 2001-09-25 | 2003-04-03 | Pharmacia Corporation | Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole |
EP1429749A2 (en) | 2001-09-26 | 2004-06-23 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
WO2003103640A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International, Ltd | Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
US20040156895A1 (en) * | 2002-11-12 | 2004-08-12 | Elan Pharma International Ltd. | Solid dosage forms comprising pullulan |
US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
EP1938803A3 (en) * | 2003-03-03 | 2010-10-27 | Elan Pharma International Limited | Formulations comprising nanoparticulate meloxican |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
GB0418791D0 (en) | 2004-08-23 | 2004-09-22 | Glaxo Group Ltd | Novel process |
US9149433B2 (en) * | 2004-11-30 | 2015-10-06 | Basf Corporation | Method for formation of micro-prilled polymers |
KR20080047509A (ko) * | 2005-05-23 | 2008-05-29 | 엘란 파마 인터내셔널 리미티드 | 혈소판 응집 억제제를 함유하는 나노입자형 조절 방출조성물 |
CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
EP2172193A1 (en) | 2008-10-02 | 2010-04-07 | Capsulution Nanoscience AG | Improved nanoparticulate compositions of poorly soluble compounds |
US7828996B1 (en) | 2009-03-27 | 2010-11-09 | Abbott Cardiovascular Systems Inc. | Method for the manufacture of stable, nano-sized particles |
AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
JP5499703B2 (ja) * | 2009-12-28 | 2014-05-21 | ライオン株式会社 | イブプロフェン含有製剤 |
RS56023B1 (sr) | 2011-07-22 | 2017-09-29 | Chemocentryx Inc | Kristalni oblik natrijumove soli 4-terc-butil-n-[4-hlor-2-(1-okso-piridin-4-karbonil)-fenil]-benzensulfonamida |
CN103813793A (zh) | 2011-07-22 | 2014-05-21 | 葛兰素史克知识产权开发有限公司 | 4-叔丁基-n-[4-氯-2-(1-氧基-吡啶-4-羰基)-苯基]-苯磺酰胺钠盐的多晶型 |
KR20190075172A (ko) | 2011-09-01 | 2019-06-28 | 글락소 그룹 리미티드 | 신규한 결정 형태 |
KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
US9393202B2 (en) * | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
PT3160958T (pt) | 2014-06-25 | 2021-04-07 | Glaxosmithkline Ip Dev Ltd | Sais cristalinos de (s)-6-((1-acetilpiperidin-4-il)amino)- n-(3-(3,4-di-hidroisoquinolin-2(1h)-il)-2- hidroxipropil)pirimidina-4-carboxamida |
US20170283404A1 (en) | 2014-09-08 | 2017-10-05 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide |
WO2016086950A1 (en) | 2014-12-03 | 2016-06-09 | Rontis Hellas S.A. | Pharmaceutical composition containing non-lipophilic hydrophobic drug and process for the preparation thereof |
JPWO2016098785A1 (ja) | 2014-12-15 | 2017-09-21 | エム・テクニック株式会社 | 有機物微粒子の製造方法及び有機物微粒子の改質方法 |
EP3528792A1 (en) | 2016-10-20 | 2019-08-28 | Dukebox SP. Z O.O. | A method of manufacturing a solution of nsaid nanoparticles |
JPWO2020179701A1 (da) | 2019-03-01 | 2020-09-10 | ||
WO2021033633A1 (ja) | 2019-08-16 | 2021-02-25 | 塩野義製薬株式会社 | 有機物ナノ粒子の製造方法及び有機物ナノ粒子 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1282405C (en) * | 1984-05-21 | 1991-04-02 | Michael R. Violante | Method for making uniformly sized particles from water-insoluble organic compounds |
IT1227626B (it) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
SE464743B (sv) * | 1989-06-21 | 1991-06-10 | Ytkemiska Inst | Foerfarande foer framstaellning av laekemedelspartiklar |
DK546289D0 (da) * | 1989-11-02 | 1989-11-02 | Danochemo As | Carotenoidpulvere |
IT1243342B (it) * | 1990-07-13 | 1994-06-10 | Farcon Ag | Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
-
1993
- 1993-06-01 DK DK93914224.6T patent/DK0644755T3/da active
- 1993-06-01 CA CA002118517A patent/CA2118517C/en not_active Expired - Lifetime
- 1993-06-01 EP EP93914224A patent/EP0644755B1/en not_active Expired - Lifetime
- 1993-06-01 HU HU9403543A patent/HUT70952A/hu unknown
- 1993-06-01 AU AU43964/93A patent/AU677783B2/en not_active Ceased
- 1993-06-01 JP JP50151594A patent/JP4439590B2/ja not_active Expired - Lifetime
- 1993-06-01 WO PCT/US1993/005082 patent/WO1993025190A1/en active IP Right Grant
- 1993-06-01 AT AT93914224T patent/ATE150297T1/de not_active IP Right Cessation
- 1993-06-01 DE DE69309056T patent/DE69309056T2/de not_active Expired - Lifetime
- 1993-06-01 ES ES93914224T patent/ES2101323T3/es not_active Expired - Lifetime
- 1993-06-09 MX MX9303452A patent/MX9303452A/es unknown
-
1997
- 1997-03-21 GR GR970400553T patent/GR3022880T3/el unknown
-
2009
- 2009-04-07 JP JP2009092791A patent/JP2009197003A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP4439590B2 (ja) | 2010-03-24 |
DE69309056T2 (de) | 1997-09-18 |
CA2118517A1 (en) | 1993-12-23 |
HUT70952A (en) | 1995-11-28 |
GR3022880T3 (en) | 1997-06-30 |
HU9403543D0 (en) | 1995-02-28 |
JPH08501073A (ja) | 1996-02-06 |
CA2118517C (en) | 2003-10-14 |
ES2101323T3 (es) | 1997-07-01 |
JP2009197003A (ja) | 2009-09-03 |
AU677783B2 (en) | 1997-05-08 |
ATE150297T1 (de) | 1997-04-15 |
EP0644755B1 (en) | 1997-03-19 |
AU4396493A (en) | 1994-01-04 |
MX9303452A (es) | 1994-01-31 |
WO1993025190A1 (en) | 1993-12-23 |
EP0644755A1 (en) | 1995-03-29 |
DE69309056D1 (de) | 1997-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0644755T3 (da) | Overflademodificerede NSAID-nanopartikler | |
ATE174506T1 (de) | Zusammensetzungen enthaltend nsaid-nanopartikel | |
ATE195416T1 (de) | Oberflächenmodifizierte arzneimittel-nanopartikel | |
NO932403D0 (no) | Overflatemodifiserte anticancer-nanopartikler |